Citation

Leen JLS, Juurlink DN. Can. J. Anaesth. 2019; 66(4): 414-421.

Vernacular Title

Carfentanil: étude narrative de sa pharmacologie et problématiques de santé publique.

Affiliation

Sunnybrook Research Institute, Toronto, ON, Canada. dnj@ices.on.ca.

Copyright

(Copyright © 2019, Springer)

DOI

10.1007/s12630-019-01294-y

PMID

30666589

Abstract

Carfentanil is a synthetic fentanyl analogue approved for veterinary use. It is a mu-opioid receptor agonist with an estimated analgesic potency approximately 10,000 times that of morphine and 20-30 times that of fentanyl, based on animal studies. Since 2016, an increasing number of reports describe detection of carfentanil in the illicit drug supply. Little is known about the pharmacology of carfentanil in humans. Its high potency and presumed high lipophilicity, large volume of distribution, and potential active metabolites have raised concerns about the management of people exposed to carfentanil as well as the safety of first responders. Exposed individuals exhibit features of an opioid toxidrome and respond to opioid antagonists such as naloxone, although empiric dose requirements are unknown and very high doses may be required. Rare reports of suspected accidental poisoning of first responders have not been analytically confirmed and are unlikely to represent true poisoning. General occupational hygiene measures, including regular decontamination with soap and water, basic personal protective equipment (nitrile gloves, N95 mask, and eye goggles), and ready access to naloxone are generally sufficient in most circumstances.

Language: en